Nature Communications (Apr 2025)

Uncovering nitroxoline activity spectrum, mode of action and resistance across Gram-negative bacteria

  • Elisabetta Cacace,
  • Manuela Tietgen,
  • Meike Steinhauer,
  • André Mateus,
  • Tilman G. Schultze,
  • Marina Eckermann,
  • Marco Galardini,
  • Vallo Varik,
  • Alexandra Koumoutsi,
  • Jordan J. Parzeller,
  • Federico Corona,
  • Askarbek Orakov,
  • Michael Knopp,
  • Amber Brauer-Nikonow,
  • Peer Bork,
  • Celia V. Romao,
  • Michael Zimmermann,
  • Peter Cloetens,
  • Mikhail M. Savitski,
  • Athanasios Typas,
  • Stephan Göttig

DOI
https://doi.org/10.1038/s41467-025-58730-5
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Nitroxoline is a bacteriostatic quinoline antibiotic, known to form complexes with metals. Its clinical indications are limited to uncomplicated urinary tract infections, with a susceptibility breakpoint only available for Escherichia coli. Here, we test > 1000 clinical isolates and demonstrate a much broader activity spectrum and species-specific bactericidal activity, including Gram-negative bacteria for which therapeutic options are limited due to multidrug resistance. By combining genetic and proteomic approaches with direct measurement of intracellular metals, we show that nitroxoline acts as a metallophore, inducing copper and zinc intoxication in bacterial cells. The compound displays additional effects on bacterial physiology, including alteration of outer membrane integrity, which underpins nitroxoline’s synergies with large-scaffold antibiotics and resensitization of colistin-resistant Enterobacteriaceae in vitro and in vivo. Furthermore, we identify conserved resistance mechanisms across bacterial species, often leading to nitroxoline efflux.